Canadian biotechnology company VoxCell has appointed Graham Craig as Chief Commercial Officer (COO). 

Craig joins VoxCell from clinical-stage biotechnology company AbCellera with experience in commercialisation and strategic partnerships across the pharmaceutical and biotech sectors. Craig will lead VoxCell’s commercial strategy, including global business development, strategic partnerships, and go-to-market execution as the industry accelerates adoption of New Approach Methodologies (NAMs). 

The appointment comes as VoxCell sets its sights on growth driven by increasing demand for predictive, human-relevant non-clinical models.   

“VoxCell is addressing a clear and growing market need for the provision of preclinical translation through models that more closely reflect human biology,” Craig said.  

“With increasing regulatory and industry alignment on NAMs, our vascularised tissue models offer a compelling path to quickly generate decision-enabling data, helping teams prioritize the right programmes earlier and reduce late-stage failure risk.  

“It’s an exciting time to join the company as we focus on expanding access to the platform through partnerships and customer programs globally.” 

VoxCell’s vascularised 3D tissue models replicate key features of the human vascular microenvironment, enabling the evaluation of drug penetration, extravasation, efficacy, and vascular toxicity behaviours single physiologically relevant system. 

Bruno Quinney, Content Team, DDW